Maintenance plasma exchange treatment for muscle specific kinase antibody positive myasthenia gravis patients by Yamada, Chisa et al.
Case Report
Maintenance Plasma Exchange Treatment
for Muscle Specific Kinase Antibody Positive
Myasthenia Gravis Patients
Chisa Yamada,1* James W. Teener,2 Robertson D. Davenport,1 and Laura Cooling1
1Division of Transfusion Medicine, Department of Pathology, University of Michigan, Ann Arbor, Michigan
2Division of Neurology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan
Abstract Background:Anti-muscle specific kinase antibody positive myasthenia gravis (MuSK MG) is often
characterized by a relatively severe and progressive course, refractoriness to standard myasthenia gravis (MG)
medications, and an increased risk of myasthenic crisis. We report here successful management of three MuSK
MG patients using maintenance therapeutic plasma exchange (TPE) treatment for up to 4.5 years. Materials:
The study was a 5-year retrospective review of all MG patients treated with TPE between 2008 and 2013 at Uni-
versity of Michigan. Inclusion criteria of MuSK MG were positive for anti-MuSK antibodies and a diagnosis of
MuSK MG by staff neurologists. Patient data included age, gender, diagnostic testing results, medications, and
the dates and response to TPE treatments. Results: A total of 153 MG patients underwent at least one course of
TPE between 2008 and 2013. A total of 12 patients (7.8%) were positive for anti-MuSK antibodies. Patients
were predominantly female (83.3%) and a median age of onset was 46-years old. Three MuSK MG patients
were successfully managed with maintenance TPE. Conclusion: Maintenance TPE may be an effective option
for MuSK MG patients. The key of successful maintenance treatment at our institution has been to tailor the
TPE frequency for each individual, and to modify the treatment interval in conjunction with medical manage-
ment. J. Clin. Apheresis 30:314–319, 2015. VC 2014 Wiley Periodicals, Inc.
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INTRODUCTION
Approximately 80% of patients with myasthenia
gravis (MG) have measureable serum antibodies to the
acetylcholine receptor (AchR) [1]. Historically, the
remaining 20% of patients have been deemed “sero-
negative.” Recently, additional auto-antibodies to other
neuromuscular junction proteins have been discovered
in these patients. Examples include antibodies directed
against muscle-specific kinase (MuSK) [1], the muscle
proteins titin or ryanodine [2], and most recently to lip-
oprotein receptor-related protein 4 (Lrp4) [3]. Other
potential antigenic targets include neural agrin which
binds to LRP4 and CoIQ which is a part of acetylcho-
linesterase complex [4].
MuSK is an important protein for AchR molecule
clustering necessary for efficient signal transduction in
the neuromuscular junction [4]. Many reports have
been published characterizing anti-MuSK antibody
(MuSK Ab) and MuSK Ab positive MG (MuSK MG)
patients. The prevalence of MuSK Ab in sero-negative
MG patients varies from 0 to 70% [1,5–7]. MuSK MG
patients are predominantly female and the age of onset
of symptoms is usually in the fourth decade of life
[7–10]. Compared to anti-AchR positive MG (AchR
MG) patients, they tend to have more severe or refrac-
tory clinical symptoms, more rapidly progressive
course, and an increased risk of myastenic crisis. When
treated with acetylcholinesterase inhibitors, these
patients seem to have an increased tendency to experi-
ence nicotinic and muscarinic side effects such as fas-
ciculations and gastrointestinal symptoms. Three main
clinical patterns have been observed in MuSK MG
patients [7,9]. One pattern is characterized by marked
oculobulbar weakness with facial and tongue atrophy
(Type 1). The second pattern shows prominent neck,
shoulder, and respiratory involvement but not ocular
weakness (Type 2). The third pattern is not distinguish-
able from AchR MG patients (Type 3). MuSK MG
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patients also differ somewhat in the results of diagnos-
tic testing such as lower diagnostic yield in repetitive
nerve stimulation (RNS), frequently abnormal single-
fiber electromyography (SFEMG) of cranial nerve-
innervated muscles, myopathy-like routine electromy-
ography (EMG), and often normal thymus gland
pathology [7–10]. Regarding therapy: they may
respond poorly to anticholinesterase treatment, and
some do not respond well to intravenous immunoglob-
ulin (IVIG). However, most seem to respond favorably
to immunosuppressive therapy and therapeutic plasma
exchange (TPE) [7–10].
TPE is frequently employed for all types of myas-
thenia, with most patients receiving 5–7 TPEs as treat-
ment for a myasthenic flare or crisis. TPE may be
especially helpful for MuSK MG patients, since 93%
of those patients showed improvement of symptoms
after TPE but little effect from IVIG [10]. Although
treatment with several different immunosuppressive
agents is effective in treatment of MuSK MG, such
treatment may have toxic side effects in many patients,
or may not be fully effective. In such cases, use of
maintenance TPE may be an effective addition to the
treatment regimen. We here report our experience with
maintenance TPE treatment in three MuSK MG
patients and its outcomes to date.
MATERIALS AND METHODS
Study Design
We performed a retrospective investigation of aphe-
resis service records between January 2008 and
December 2013 at the University of Michigan Health
System (UMHS). A total of 153 MG patients who
received TPE were identified. Among them, three
patients with MuSK Abs who have received mainte-
nance TPE were identified. All patients consented to
participate ASFA rare disease registry and subsequent
publications as deidentified participants.
Each patient’s age, sex, race, age of onset of MG,
symptoms, MuSK Ab test results, EMG result, dates of
TPE procedures, and medications were retrieved from
the medical record at UMHS. MuSK Ab was tested at
Athena Diagnostics (Marlborough, MA).
TPE procedures were performed using either the
Cobe SpectraVR or Spectra OptiaVR Apheresis System
(TerumoBCT, Lakewood, CO), and one plasma volume
was exchanged with 5% albumin in one procedure.
The amount of anticoagulant citrate dextrose solution
A (ACD-A) was calculated by the apheresis machine
using each patient’s total blood volume calculated
based on sex, height, and weight to meet the set infu-
sion rate of 0.8–1.0 mL/min/liter of total blood volume.
About 2.4 mEq Ca11 in the form of calcium gluconate
or chloride was added to each 500 mL albumin bottle
to prevent citrate toxicity symptoms.
RESULTS
In total, 153 MG patients received TPE between
January 2008 and December 2013. Of these, 87
patients (56.9%) were female and 66 patients (43.1%)
were male. Among them, 12 patients (7.8%) had
MuSK Abs, with 10 females (83.3%) and 2 males
(16.7%). The age of onset of the symptoms in this
group of MuSK-positive patients was from 11- to 66-
years old: the second, 3rd and 4th decade in one
patient each, 5th decade in five patients, 6th and 7th
decade in two patients each. A median age was 46
years old (mean, 44.0 years old). One patient died due
to sepsis in 2009. Among these 12 patients, 2 patients
have been receiving maintenance TPE and one patient
received it until her condition improved markedly due
to medications for other disease. These three MuSK
MG patients are presented here and the data is sum-
marized in Table I.
Case 1
A 63-year-old female developed progressive dyspnea
and dysphonia in 2004 at age 54. As her condition
worsened, she developed confusion and lethargy, and
she required mechanical ventilation at an outside hospi-
tal (OSH) in 2005. Her cardiopulmonary examinations
were all negative and she was initially diagnosed with
phrenic nerve palsy. Because the phrenic neuropathy
was thought to be immune-mediated, she was treated
with IVIG. She responded well to IVIG and was back
to her normal activities. In 2007, however, she devel-
oped worsening dyspnea and fatigue and was trans-
ferred to UMHS for further management. She had no
focal neurologic deficits on physical examination at
that time. Her sleep study showed frequent oxygen
desaturations to 67–80% and she required biphasic pos-
itive airway pressure (BiPAP) for hypercarbia at night.
Electrodiagnostic studies revealed decremental
responses up to 18% on RNS and increased jitter on
SFEMG was noted. MuSK Ab was reported to be posi-
tive subsequently, and diagnosis of MuSK MG was
confirmed. Pyridostigmine did not improve her symp-
toms, but she responded well to IVIG.
Although her clinical symptoms had improved with
IVIG, she developed persistent prominent symptoms of
facial weakness and fatigueable dysarthria with pro-
longed speech over time. She also continued to require
BiPAP at night. Additional therapy was deemed neces-
sary; therefore, five TPE treatments (twice a week)
were performed in June 2009. She responded to TPE
well and felt nearly normal after five TPE. She
received another five TPE for mildly worsened symp-
toms in December 2009 and moved on to maintenance
TPE every 8 weeks in March 2010. She responded
well to TPE every time, however, she had a significant
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return in symptoms by 8 weeks. Therefore, interval
shortened to 6 weeks in August 2010 and eventually 4
weeks in September 2011. Since then, her symptoms
have been stable with slight dysarthria and ptosis at
night. The TPE interval is periodically shortened to
every 3 weeks due to mild exacerbation of MG symp-
toms secondary to infection or stress. She has not had
diplopia.
Case 2
A 41-year old female was admitted to the hospital
with acute respiratory failure and dysphonia, and was
diagnosed with MuSK MG in 2011 at age 38. She had
been having progressive dysarthria for two years and
progressive dysphagia for 6 months prior to presenta-
tion to the emergency department at an OSH. She was
found to be hypercarbic and started BiPAP and eventu-
ally intubated due to declining mental status. Chest X-
ray showed left-sided atelectasis and left hemidiaphrag-
matic elevation. She was transferred to UMHS for fur-
ther management. EMG was normal and anti-AchR
antibody was negative. However, anti-MuSK antibody
was positive leading to the diagnosis of MuSK MG. A
swallowing study revealed diffuse pharyngeal weakness
and failure of epiglottic inversion, deep penetration,
and aspiration during swallows, as well as aspiration
from residue in between swallows.
She received total 10 TPE treatments; three times a
week at the beginning and twice a week after five
treatments, along with prednisone 10 mg daily with
remarkable improvement of the symptoms. However,
her mild dysarthria worsened again in 6 weeks. There-
fore, she received eight TPE divided twice a week fol-
lowed by three weekly TPE with good response. After
the third weekly TPE, she developed central catheter-
related polymicrobial (Enterobacter cloacae, Klebsiella
pneumonia, and coagulase negative staph) blood infec-
tion leading to pneumonia, and the catheter was
removed. Laboratory data on admission showed
increased WBC count (13,700/mm3) with increased
absolute neutrophil count (12,100/mm3) and decreased
TABLE I. Summary of Three Cases (as of 31 August, 2014)
Case 1 Case 2 Case3
Sex Female Female Female
Age (onset/current) 54/63 38/41 43/48
Anti-MuSK Aba Positive Positive Positive
Anti-AchR Abb Negative Negative Negative
EMG
RNSc  Decrement up to 18%  Normal  Mild decrement
SFEMGd  Increased jitter  Not done  Not done
Symptoms  Respiratory failure  Respiratory failure  Dysarthria
 Dysarthria  Dysarthria  Dysphagia
 Dysphonia  Dysphonia  Ptosis
 Fatigue  Dysphagia  Diplopia
 Mild ptosis  Fatigue  Upper extremity weakness
 Neck weakness
Current immunosuppressives  None  Prednisone 5 mg  Cyclosporine 100 mg (for
HLH syndromee)
 MMFf 2.5 g
 Pyridostigmine 60 mg  Decadron 0.375 mg (for
arthralgia)
Access and issues Peripheral Fistula after 3 TPEg courses,
infection twice
Peripheral
Induction TPEg 5 TPEg 3 2 courses 10, 6, 7, 6 TPEg 5 and 3 TPEg
Maintenance TPEg Every 3–8 weeks Every 7–14 days Every 2–3 weeks
Duration of maintenance TPEg 53 months 16 months 43 months
Thymectomy No No No
Current condition Stable with minimum
symptoms
Stable, mild fatigue Stable, no MGh symptoms
aAnti-MuSK Ab: anti-muscle specific kinase antibody.
bAnti-AchR Ab: anti-acetylcholine receptor antibody.
cRNS: repetitive nerve stimulation.
dSFEMG: single-fiber electromyography.
eHLH syndrome: hemophagocytic lymphohistiocytosis syndrome.
fMMF: mycophenolate mofetil.
gTPE: therapeutic plasma exchange.
hMG: myasthenia gravis.
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absolute lymphocyte count (300/mm3). She was treated
with prednisone 10–15 mg daily, mycophenolate mofe-
til 2,000–2,500 mg daily, and pyridostigmine as needed
at that time.
After she recovered from pneumonia, she gradually
developed generalized fatigue, neck weakness, short-
ness of breath with accessory muscle use on breathing,
in addition to mild dysphonia as a baseline in Decem-
ber 2012. Since TPE was the most effective treatment
evidenced by her past history, she received seven TPE
treatments divided twice a week in December 2012
and January 2013. An arteriovenous fistula was placed
on her right forearm and she received six TPE divided
twice a week in March 2013. Thereafter, she moved on
to weekly maintenance TPE from April 2013. Her
symptoms were stable and she could reduce the treat-
ment frequency from once a week to every other week
for the last 6 months of 2013. However, she developed
symptomatic recurrence some days before each TPE
and the TPE interval was shortened to every 10 days
in 2014. Then, her fistula failed in April 2014, and she
could not receive TPE for more than 1 month. During
this time, she developed significant shortness of breath,
fatigue, and dysphagia. A central catheter was placed
despite her history of catheter-related infection for
TPE. She again developed catheter-related sepsis and
pulmonary embolism in July 2014; both were success-
fully treated. She is now receiving maintenance TPE
every 7–10 days and is doing well with only mild dys-
phonia and fatigue as her baseline. She is on predni-
sone alternating 5 mg and 10 mg daily, mycophenolate
mofetil 2,500 mg daily, and pyridostigmine as needed,
in addition to BiPAP use during sleep. She has not had
ptosis or diplopia. She received another fistula place-
ment in November 2014.
Case 3
A 48-year-old female with progressive ptosis, diplo-
pia, dysarthria, upper extremity weakness, and mild
dysphagia was diagnosed with MuSK MG in 2009 at
age 43. Anti-AchR antibody was negative and a brain
MRI was normal. Electrodiagnostic testing showed a
mild decrement with RNS of the right facial nerve, but
was otherwise normal. She was begun on pyridostig-
mine without much improvement, then started predni-
sone with some improvement. Because she still had
dysarthria, dysphagia, diplopia, and neck pain, she
received five TPE over 10 days. She experienced
remarkable improvement in her symptoms. However,
her symptoms worsened in two weeks after the last
TPE, and she received additional three TPE divided
twice a week. Since she responded well to TPE, main-
tenance TPE was initiated every other week from Janu-
ary 2010. Her prednisone dose was slowly tapered
from 30 mg to 10 mg. The TPE frequency was
decreased to every 3 weeks for 2.5 years. However,
she experienced shortened symptom free days between
each TPE treatment after her prednisone was further
tapered to 7.5 mg per day. Because of prednisone-
related side effects, frequent TPE was employed rather
than increasing the dose of prednisone. The TPE fre-
quency was increased to every other week again from
December 2012. She was also on azathioprine 200 mg
daily, and pyridostigmine as needed, even though she
did not feel substantial benefit from pyridostigmine.
She was relatively stable until she had a right tym-
panoplasty for a cholesteatoma in August 2013 at an
OSH. Because she could not receive TPE locally, her
azathioprine dose was increased. She developed cyto-
megalovirus and parvovirus infections with acute respi-
ratory distress syndrome, hemophagocytic
lymphohistiocytosis (HLH syndrome), and multi-organ
failure. She was hospitalized for 2 months but
responded well on etoposide. She received two TPE
treatments during her admission at times when her MG
symptoms flared slightly. As she has been treated with
higher doses of immunosuppression for the HLH syn-
drome, her MuSK-MG has become far less sympto-
matic, and she is not currently requiring TPE. She is
currently receiving low dose dexamethasone and cyclo-
sporine 100 mg daily for her HLH syndrome.
DISCUSSION
MuSK MG has been reported to account for a sig-
nificant part of “sero-negative” MG for over a decade.
MuSK Abs are predominantly non-complement fixing
IgG4 subclass [11,12] that may interfere with neuro-
muscular function by several mechanisms. MuSK anti-
bodies may inhibit binding between MuSK and Lrp4
[13], they may suppress the endplate density of MuSK
leading to down-regulation of MuSK signaling at the
postsynaptic membrane [14], and may also cause pre-
synaptic functional abnormalities leading to decreased
Ach release [15]. It is well known that MuSK MG
patients have different clinical course compared to
AchR MG patients and a different treatment approach
may be necessary.
The MuSK MG patients who have received TPE at
the UMHS have the following demographic: 83.3% of
patients are female and the age of onset was most often
in 5th decade, which is similar to many previous
reports [7–10]. All three patients treated with mainte-
nance TPE had bulbar symptoms. Cases 1 and 2 can
be categorized in Type 2 (prominent neck, shoulder,
and respiratory involvement but not ocular weakness)
and Case 3 can be categorized in Type 1 (marked ocu-
lobulbar weakness with facial and tongue atrophy).
EMG results varied in the three patients. However,
RNS was normal in one patient and only mild
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decrement was seen in another patient. SFEMG was
positive in one patient and not tested in other two
patients.
Treatment for classic MG patients consists of (1)
symptomatic treatment such as acetylcholinesterase
inhibitors, (2) chronic immunomodulatory treatment
such as corticosteroids, azathioprine, cyclosporine,
mycophenolate mofetil, methotrexate, cyclophospha-
mide, tacrolimus, and more recently rituximab, (3)
rapid immunomodulatory treatment such as high dose
steroid, TPE, or IVIG, and (4) surgical treatment such
as thymectomy. MuSK MG patients tend to respond
poorly to acetylcholinesterase inhibitors and may not
respond as well to IVIG. The thymus gland is typically
normal. Therefore, immunomodulatory treatments, both
chronic and rapid, are more important for those with
MuSK MG. All of our MuSK MG patients presented
here also had poor response to pyridostigmine and
have no evidence of a thymoma. With the exception of
Case 1, who initially responded well to IVIG, all three
cases were ultimately refractory to IVIG therapy.
Most MG patients respond well to steroid therapy.
However, short- and long-term steroid use is associated
with multiple and possibly severe side effects including
susceptibility to infection (which can trigger a flare of
symptoms in MG patients), diabetes, hypertension, gas-
trointestinal bleeding, mood swings, osteoporosis, and
Cushingoid appearance. The patients’ response to other
immunosuppressive mediations varies depending on
patient, and so do the side effects. Azathioprine can
cause bone marrow suppression and liver dysfunction,
cyclosporine can cause renal dysfunction and paresthe-
sias, mycophenolate mofetil can cause gastrointestinal
symptoms and susceptibility for infection, methotrexate
and cyclophosphamide can also cause gastrointestinal
symptoms, liver dysfunction, bone marrow suppression,
and infection, tacrolimus can cause renal dysfunction
and opportunistic infections [16]. Recently rituximab is
reported to be beneficial for MuSK MG patients as a
long-lasting treatment [17–19] and likely will become
increasingly used to treat MuSK-MG. However, pro-
longed B-cell depletion is reported [20] in addition to
minor side effects such as fever, nausea, headache, and
dyspnea [16]. Angina, cardiac dysrhythmia, anemia,
leukopenia, and thrombocytopenia also have been
reported in MG patients [21]. Importantly; rituximab is
currently not approved for treatment of MG and may
not be covered by public and private insurers. The
effect of IVIG also varies depending on individual.
Our study shows that maintenance TPE may be a
viable alternative treatment for MuSK MG patients
who fail to respond or are intolerant of standard immu-
nosuppressive therapy. In the three cases reported here,
we were able to achieve relatively prolonged periods
of excellent symptom control using maintenance TPE.
The frequency of treatment is adjusted based upon the
patients’ report of symptom control and the physicians’
evaluation. Case 1 receives TPE every 4 weeks, but
occasionally every 3 weeks when she has infection or
predictable emotional or physical stress. She is stable
with minimal symptoms without medications. Case 2
had frequent vascular access problems, and her symp-
toms remarkably worsened without TPE despite treat-
ment with oral immune-modulating medications. Case
3 was also stable with modification of TPE frequency
depending on her symptoms in conjunction with medi-
cations. She currently is not requiring TPE, but is
receiving aggressive immunosuppression for HLH
syndrome.
Our three patients did not experience any adverse
events to TPE procedures such as hypotensive or aller-
gic reactions, citrate side effects, bleeding episodes,
and procedure-related anemia. The shortest interval of
maintenance TPE employed with these patients is 7
days, which may be sufficient to recover from
decreased coagulation factors, Hct, and immunoglobu-
lin levels when liver and kidney functions are normal.
However, the access for frequent TPE is always a con-
cern and one patient had catheter-related infection
twice. A fistula or a port placement may be required
when peripheral access is poor. One of our patients has
been able to receive maintenance TPE every 2–4
weeks for several years using only peripheral access,
and another was treated with peripheral access exclu-
sively. Infection has to be monitored carefully with
periodical tests for WBC/neutrophil/lymphocyte counts
and immunoglobulin levels since infectious risk is high
in these patients due to immunosuppression.
CONCLUSIONS
We report three MuSK MG patients who have
received maintenance TPE treatment with favorable
outcome. Maintenance TPE may be an effective option
for MuSK MG patients who cannot tolerate medica-
tions, or receive incomplete benefit from standard
immunosuppression. The key to successful maintenance
treatment at our institution has been to tailor the TPE
frequency for each individual, and to modify the treat-
ment interval in conjunction with medical management.
In some patients, peripheral access may be adequate
for even long-term TPE, but many patients will need
alternative access. A fistula may be considered for
such patients.
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